Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-M...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Niktoreh, Naghmeh, Lerius, Beate, Zimmermann, Martin, Gruhn, Bernd, Escherich, Gabriele, Bourquin, Jean-Pierre, Dworzak, Michael, Sramkova, Lucie, Rossig, Claudia, Creutzig, Ursula, Reinhardt, Dirk, Rasche, Mareike
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312035/
https://ncbi.nlm.nih.gov/pubmed/30093401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.191841
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires